ENDPOINTS

#ASCO25: Enhertu extends life by three months for some stomach cancer patients

CHICAGO — For AstraZeneca and Daiichi Sankyo, the antibody drug conjugate Enhertu has become a recurring topic at the annual American Society of Clinical Oncology meeting. Their latest data presented Saturday showed that previously treated ...

May 31, 2025 - 13:04
 0
#ASCO25: Enhertu extends life by three months for some stomach cancer patients
CHICAGO — For AstraZeneca and Daiichi Sankyo, the antibody drug conjugate Enhertu has become a recurring topic at the annual American Society of Clinical Oncology meeting. Their latest data presented Saturday showed that previously treated ...
Read More

Tags:

Previous Article

#ASCO25: Immatics reports more early-stage data for melanoma cell therapy with p...

Next Article

#ASCO25: Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda com...

Related Posts

Sarepta seeks to expand Duchenne gene therapy Elevidys use to toddlers

Sarepta seeks to expand Duchenne gene therapy Elevidys ...

May 16, 2025  0

Trump's drug price plan is light on details, may have little impact

Trump's drug price plan is light on details, may have l...

May 12, 2025  0

Big pharma companies explain why tariffs will harm US investments 

Big pharma companies explain why tariffs will harm US i...

May 29, 2025  0